Replies to post #2381 on EOM Pharmaceutical Holdings Inc. (IMUC)

[erostratus]

I'm under the impression that since they are blinded they won't have access to the event, merely when the final analysis is complete, which is done by a third party. See the earnings call link posted.

No one inside or outside the company has had or will have any basis on which to speculate about the outcome of this trial, until it is completed and the data are analyzed.

I want to emphasize that the company personnel remain blinded to the data from the interim analysis and will remain blinded to the results from this trial until we receive the top-line data read-out from the contract research organization operating the trial. -

Now, after talking to someone who worked in the field, I was informed that analysis is usually expected to take a long time when the results are positive, since you must triple and quadruple check everything in order to make sure that all factors are accounted for and to see that efficacy is substantiated rather than mis-perceived. In cases of clear failure, this is usually starkly clear and analysis should not take long. No need to double triple check anything when results look prima facie dismal...People dying at the same rate as placebo leaves not much room for analysis.



Take my optimism with a grain of salt though, we will only know for sure when results are announced